ASP Isotopes Inc. Announces Closing of Initial Public Offering and Nasdaq Listing
ASP Isotopes Inc. Announces Closing of Initial Public Offering and Nasdaq Listing
BOCA RATON, FL / ACCESSWIRE / November 15, 2022 / ASP Isotopes Inc. ("ASPI" or the "Company") (Nasdaq:ASPI), an advanced materials company dedicated to the development of technology and processes that will allow for the production of isotopes that may be used in several industries, today announced the closing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses.
佛羅裏達州博卡拉頓/ACCESSWIRE/2022年11月15日/亞洲網加利福尼亞州聖何塞10月23日電納斯達克(ASPI)是一家先進材料公司，致力於開發技術和工藝，使其能夠生產可用於多個行業的同位素。該公司今天宣佈，在扣除承銷折扣、佣金和其他發售費用之前，以每股4美元的公開發行價首次公開發行125萬股普通股，總收益約為500萬美元。
The shares began trading on the Nasdaq Capital Market LLC on November 10, 2022, under the ticker symbol "ASPI."
該股於2022年11月10日在納斯達克資本市場開始交易，股票代碼為“ASPI”。
The Company intends to use the net proceeds of the offering for the completion of its Molybdenum enrichment facility in Pretoria, South Africa and other general corporate purposes.
本公司擬將發售所得款項淨額用於完成其位於南非比勒陀利亞的鉬精選設施及其他一般企業用途。
Revere Securities LLC is acted as sole book-running manager for the offering
Revere Securities LLC擔任此次發行的唯一簿記管理人
A registration statement on Form S-1 (File No. 333-267392), is filed with the Securities and Exchange Commission ("SEC") and was declared effective on November 9, 2022. The final prospectus relating to the offering is available on the SEC's website at http://www.sec.gov . Electronic copies of the final prospectus relating to this offering are also available, from: Revere Securities LLC, 650 5th Ave, New York, NY 10019, United States.
S-1表格的註冊聲明(文件編號333-267392)已提交給美國證券交易委員會(“美國證券交易委員會”)，並於2022年11月9日宣佈生效。與此次發行相關的最終招股説明書可在美國證券交易委員會網站http://www.sec.gov上查閲。與此次發行有關的最終招股説明書的電子版也可從以下地址獲得：Revere Securities LLC，地址：紐約第五大道650號，NY 10019，美國。
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
本新聞稿不應構成出售這些證券的要約或徵求購買這些證券的要約，也不應在任何州或司法管轄區出售這些證券，在這些州或司法管轄區的任何州或司法管轄區，在根據任何此類州或司法管轄區的證券法註冊或獲得資格之前，此類要約、徵求或出售將是非法的。
About ASP Isotopes Inc.
關於ASP Isotopes Inc.
ASPI is an advanced materials company dedicated to the development of technology and processes that will allow for the production of isotopes that may be used in several industries. We have an exclusive license to use proprietary technology, the Aerodynamic Separation Process ("ASP technology") for the production, distribution, marketing and sale of all isotopes.
ASPI是一家先進材料公司，致力於開發技術和工藝，以生產可能用於幾個行業的同位素。我們擁有使用專有技術--空氣動力分離工藝(“ASP技術”)生產、分銷、營銷和銷售所有同位素的獨家許可證。
Our initial focus is on the production and commercialization of enriched Molybdenum-100 ("Mo-100"), and are constructing a first commercial-scale Mo-100 enrichment plant located in South Africa. We believe that the Mo-100 we may develop using the ASP technology has significant potential advantages for use in the preparation of nuclear imaging agents by radiopharmacies and others in the medical industry.
我們最初的重點是濃縮鉬-100(“Mo-100”)的生產和商業化，並正在建設位於南非的第一個商業規模的鉬-100濃縮工廠。我們相信，我們可能開發的利用ASP技術開發的Mo-100在放射性藥物和其他醫療行業的核顯像劑的製備中具有顯著的潛在優勢。
We may also seek to use the ASP technology to separate Silicon-28, which we believe has potential application in the quantum computing target end market, and Carbon-14, which we believe has potential application in the pharma/agrochemical target end market. In addition, we are considering future development of the ASP technology for the separation of Zinc-68, Ytterbium-176, Zinc-67, Nickel-64 and Xenon-136 for potential use in the healthcare target end market, and Uranium-235, Chlorine -37 and Lithium-6 for potential use in the nuclear energy target end market.
我們還可能尋求使用ASP技術來分離我們認為在量子計算目標終端市場具有潛在應用的Silicon-28和我們認為在製藥/農用化學品目標終端市場具有潛在應用的Carbon-14。此外，我們正在考慮未來開發分離鋅-68、Yb-176、鋅-67、鎳-64和氙氣-136的ASP技術，用於醫療保健目標終端市場的潛在用途，以及用於核能目標終端市場的鈾-235、氯-37和鋰-6的潛在用途。
We were incorporated in Delaware in September 2021. Our principal executive offices are located at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432, and our telephone number is (561) 709-3034. Our website address is .
我們於2021年9月在特拉華州註冊成立。我們的主要執行辦公室位於佛羅裏達州博卡拉頓，郵編：33432，Suite275，Plaza Real，433，我們的電話號碼是(561)7093034。我們的網站地址是。
Forward Looking Statements
前瞻性陳述
This press release contains statements that constitute "forward-looking statements," including with respect to the proposed initial public offering and the anticipated use of the net proceeds. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the Company's offering filed with the SEC. Copies of these documents are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
本新聞稿包含構成“前瞻性陳述”的陳述，包括與擬議的首次公開募股和淨收益的預期使用有關的陳述。不能保證上述討論的發行將按所述條款完成，或根本不能保證，或發行所得淨額將按説明使用。前瞻性陳述受許多條件的制約，其中許多條件不是本公司所能控制的，包括本公司向美國證券交易委員會提交的註冊説明書和初步招股説明書的風險因素部分闡述的那些條件。這些文件的副本可以在美國證券交易委員會的網站www.sec.gov上找到。除法律要求外，本公司不承擔在本新聞稿發佈之日後更新這些聲明以進行修訂或更改的義務。
Contacts
Robert Ainscow - Chief Financial Officer
ir@aspisotopes.com
聯繫人
羅伯特·安斯考--首席財務官
郵箱：ir@aspsodiopes.com
Dave Gentry - RedChip
dave@redchip.com
戴夫·金特里-紅籌股
郵箱：dave@redchip.com
SOURCE: ASP Isotopes
來源：天冬氨酸同位素
譯文內容由第三人軟體翻譯。